EP. 5: Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs
November 28th 2022Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.
EP. 8: Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC
November 29th 2022Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.
EP. 11: Experts on the Management of Diarrhea Associated With EGFR TKIs
November 29th 2022Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
2 Commerce Drive
Cranbury, NJ 08512